The decades-old question of how long men with prostate cancer should receive hormone suppression alongside radiation therapy now has a data-driven answer that could spare thousands from unnecessary treatment toxicity while maximizing survival benefits. This finding addresses a critical clinical gap where oncologists have long relied on institutional preferences rather than evidence-based duration guidelines.
Analyzing individual patient data from 13 randomized trials spanning over 10,000 men with localized prostate cancer, researchers identified 18-24 months as the optimal duration for androgen deprivation therapy combined with radiotherapy. The meta-analysis revealed diminishing returns beyond this timeframe, with survival curves plateauing after two years of hormone suppression. For high-risk patients comprising 72% of the cohort, this duration reduced distant metastasis risk significantly compared to radiation alone, with number-needed-to-treat calculations demonstrating clear clinical benefit thresholds.
This represents a paradigm shift from the "longer is better" assumption that has driven many oncologists to prescribe 24-36 month regimens. The research landscape has been fragmented by studies testing variable durations from 6 to 36 months, making clinical decision-making challenging. The current analysis provides the first comprehensive individual patient-level evidence to guide duration decisions, potentially reducing the cardiovascular, metabolic, and quality-of-life consequences of prolonged testosterone suppression while maintaining oncologic efficacy. However, the findings primarily apply to high-risk localized disease, and practitioners must still individualize treatment based on patient-specific factors including age, comorbidities, and disease characteristics.